MX2015005056A - Antigenos ampliamente reactivos computacionalmente optimizados para influenza h1n1. - Google Patents

Antigenos ampliamente reactivos computacionalmente optimizados para influenza h1n1.

Info

Publication number
MX2015005056A
MX2015005056A MX2015005056A MX2015005056A MX2015005056A MX 2015005056 A MX2015005056 A MX 2015005056A MX 2015005056 A MX2015005056 A MX 2015005056A MX 2015005056 A MX2015005056 A MX 2015005056A MX 2015005056 A MX2015005056 A MX 2015005056A
Authority
MX
Mexico
Prior art keywords
seq
influenza
residues
polypeptide
amino acid
Prior art date
Application number
MX2015005056A
Other languages
English (en)
Spanish (es)
Inventor
Ted M Ross
Corey J Crevar
Donald M Carter Jr
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Publication of MX2015005056A publication Critical patent/MX2015005056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2015005056A 2012-11-27 2013-11-27 Antigenos ampliamente reactivos computacionalmente optimizados para influenza h1n1. MX2015005056A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730186P 2012-11-27 2012-11-27
PCT/US2013/072279 WO2014085616A1 (en) 2012-11-27 2013-11-27 Computationally optimized broadly reactive antigens for h1n1 influenza

Publications (1)

Publication Number Publication Date
MX2015005056A true MX2015005056A (es) 2015-07-23

Family

ID=50773495

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005056A MX2015005056A (es) 2012-11-27 2013-11-27 Antigenos ampliamente reactivos computacionalmente optimizados para influenza h1n1.

Country Status (13)

Country Link
US (3) US9309290B2 (enExample)
EP (1) EP2925773B1 (enExample)
JP (2) JP2016505538A (enExample)
KR (1) KR20150089005A (enExample)
CN (1) CN104797594A (enExample)
AU (2) AU2013352179B2 (enExample)
CA (1) CA2891682A1 (enExample)
HK (1) HK1212708A1 (enExample)
IN (1) IN2015DN03070A (enExample)
MX (1) MX2015005056A (enExample)
RU (1) RU2015124805A (enExample)
SG (1) SG11201503989PA (enExample)
WO (1) WO2014085616A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883171B2 (en) * 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
EP2721158B1 (en) * 2011-06-20 2017-05-03 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for h1n1 influenza
IN2014DN07399A (enExample) 2012-03-30 2015-04-24 Univ Pittsburgh
WO2016100922A1 (en) * 2014-12-19 2016-06-23 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
CN108290932A (zh) 2015-06-09 2018-07-17 圣诺菲·帕斯图尔公司 优化编码工程改造的流感蛋白的核苷酸序列的方法
US11116832B2 (en) 2016-06-03 2021-09-14 Sanofi Pasteur Inc. Modification of engineered influenza hemagglutinin polypeptides

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE376059T1 (de) 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP1851238A4 (en) 2005-02-24 2008-12-31 Univ Massachusetts FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF
WO2007011904A2 (en) 2005-07-19 2007-01-25 Dow Global Technologies Inc. Recombinant flu vaccines
WO2007072214A2 (en) 2005-12-19 2007-06-28 Novartis Vaccines And Diagnostics Srl Methods of clustering gene and protein sequences
US20080045472A1 (en) 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
AU2008331673B2 (en) * 2007-11-12 2014-12-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
SG187500A1 (en) * 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
WO2010036970A2 (en) 2008-09-25 2010-04-01 Fraunhofer Usa, Inc. Influenza vaccines, antigens, compositions, and methods
WO2010036948A2 (en) 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
KR101715418B1 (ko) 2009-04-03 2017-03-10 메리얼 인코포레이티드 뉴캐슬 질환 바이러스-벡터를 이용한 조류 백신
HRP20180706T1 (hr) * 2009-06-24 2018-06-01 Medicago Inc. Kimerna gripa nalik čestici koja sadrži hemaglutinin
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN102373184A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性支气管炎混合病毒样颗粒、制备方法和应用
US8883171B2 (en) * 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
EP2721158B1 (en) * 2011-06-20 2017-05-03 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for h1n1 influenza
AU2013217166B2 (en) 2012-02-07 2017-04-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
US9566327B2 (en) 2012-02-13 2017-02-14 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
IN2014DN07399A (enExample) * 2012-03-30 2015-04-24 Univ Pittsburgh

Also Published As

Publication number Publication date
CA2891682A1 (en) 2014-06-05
AU2013352179A8 (en) 2015-05-28
US20160166677A1 (en) 2016-06-16
RU2015124805A (ru) 2017-01-13
EP2925773B1 (en) 2018-12-26
US10017544B2 (en) 2018-07-10
KR20150089005A (ko) 2015-08-04
SG11201503989PA (en) 2015-06-29
AU2013352179A1 (en) 2015-05-14
IN2015DN03070A (enExample) 2015-10-02
EP2925773A4 (en) 2016-06-08
JP2016505538A (ja) 2016-02-25
EP2925773A1 (en) 2015-10-07
US20140147459A1 (en) 2014-05-29
HK1212708A1 (zh) 2016-06-17
US9566328B2 (en) 2017-02-14
WO2014085616A1 (en) 2014-06-05
JP2018183149A (ja) 2018-11-22
AU2018201876A1 (en) 2018-04-12
AU2013352179B2 (en) 2017-12-21
CN104797594A (zh) 2015-07-22
US20170114102A1 (en) 2017-04-27
US9309290B2 (en) 2016-04-12

Similar Documents

Publication Publication Date Title
US10562940B2 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
US10865228B2 (en) Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
AU2013217166B2 (en) Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
US10017544B2 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
HK1197685B (en) Computationally optimized broadly reactive antigens for h1n1 influenza
HK1197685A (en) Computationally optimized broadly reactive antigens for h1n1 influenza